Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, Cassingena A, Rusconi F, Esposito A, Nichelatti M, Esteller M, Siena S. Amatu A, et al. Among authors: nichelatti m. Clin Cancer Res. 2013 Apr 15;19(8):2265-72. doi: 10.1158/1078-0432.CCR-12-3518. Epub 2013 Feb 19. Clin Cancer Res. 2013. PMID: 23422094 Clinical Trial.
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S. Sartore-Bianchi A, et al. Among authors: nichelatti m. J Clin Oncol. 2007 Aug 1;25(22):3238-45. doi: 10.1200/JCO.2007.11.5956. J Clin Oncol. 2007. PMID: 17664472 Clinical Trial.
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Sartore-Bianchi A, et al. Among authors: nichelatti m. Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17. Cancer Res. 2009. PMID: 19223544
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S. Sartore-Bianchi A, et al. Among authors: nichelatti m. PLoS One. 2009 Oct 2;4(10):e7287. doi: 10.1371/journal.pone.0007287. PLoS One. 2009. PMID: 19806185 Free PMC article.
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, Meneghini V, Pioltelli P, Sacchi S, Ricci F, Nichelatti M, Zaja F, Lazzarino M, Vitolo U, Morra E. Tedeschi A, et al. Among authors: nichelatti m. Cancer. 2012 Jan 15;118(2):434-43. doi: 10.1002/cncr.26303. Epub 2011 Jul 5. Cancer. 2012. PMID: 21732338 Free article. Clinical Trial.
Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab.
Ricotta R, Vanzulli A, Moroni M, Colnago B, Oriani M, Nichelatti M, Sarnataro C, Venturini F, Di Bella S, Maiolani M, Giganti MO, Sartore-Bianchi A, Siena S. Ricotta R, et al. Among authors: nichelatti m. Clin Colorectal Cancer. 2013 Mar;12(1):45-53. doi: 10.1016/j.clcc.2012.07.001. Epub 2012 Oct 4. Clin Colorectal Cancer. 2013. PMID: 23041354
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Sartore-Bianchi A, Pietrantonio F, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomatà C, Pellegrinelli A, Bardelli A, Nichelatti M, Tosi F, De Braud F, Di Nicolantonio F, Barault L, Siena S. Sartore-Bianchi A, et al. Among authors: nichelatti m. Eur J Cancer. 2017 Jan;71:43-50. doi: 10.1016/j.ejca.2016.10.032. Epub 2016 Dec 18. Eur J Cancer. 2017. PMID: 27997874 Free article. Clinical Trial.
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
Tosi F, Magni E, Amatu A, Mauri G, Bencardino K, Truini M, Veronese S, De Carlis L, Ferrari G, Nichelatti M, Sartore-Bianchi A, Siena S. Tosi F, et al. Among authors: nichelatti m. Clin Colorectal Cancer. 2017 Sep;16(3):e153-e163. doi: 10.1016/j.clcc.2017.01.004. Epub 2017 Jan 25. Clin Colorectal Cancer. 2017. PMID: 28216246 Review.
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
Amatu A, Schirripa M, Tosi F, Lonardi S, Bencardino K, Bonazzina E, Palmeri L, Patanè DA, Pizzutilo EG, Mussolin B, Bergamo F, Alberti G, Intini R, Procaccio L, Arese M, Marsoni S, Nichelatti M, Zagonel V, Siena S, Bardelli A, Loupakis F, Di Nicolantonio F, Sartore-Bianchi A, Barault L. Amatu A, et al. Among authors: nichelatti m. Front Oncol. 2019 Jul 12;9:622. doi: 10.3389/fonc.2019.00622. eCollection 2019. Front Oncol. 2019. PMID: 31355139 Free PMC article.
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E. Montillo M, et al. Among authors: nichelatti m. J Clin Oncol. 2006 May 20;24(15):2337-42. doi: 10.1200/JCO.2005.04.6037. Epub 2006 Apr 17. J Clin Oncol. 2006. PMID: 16618945 Clinical Trial.
104 results